Feasibility and dose-escalation clinical trial of local immunotherapy for solid and brain tumors in canine cancer patient
Purpose of study
The long-term goal of this study is to add local immunotherapy to treatments for human and canine cancer. The intention is to demonstrate the injection is well tolerated and provides an optimal anti-cancer response by creating a safe and effective dose.
Benefits
While this study may not offer a direct therapeutic benefit to the participant, it contributes significantly to the development of treatments aimed at reducing local tumor burden in both canine and human cancer patients. To support participation, the study will pay $1000 towards the patient’s medical bill, the cost of the stay in ICU, medications required as a direct result of the study, and any bloodwork required for the study.
Enrollment requirements
- Dogs must have been diagnosed with an easily accessible soft tissue sarcoma with tumor size being at least 2 cm.
- The patient needs to be a suitable surgery candidate and have undergone all diagnostics considered standard of care.
- The patient must meet previously set parameters for bloodwork to be eligible for the study.
Treatment methods
After being approved for the study, surgery will be scheduled at the WSU VTH. An appointment for 7 days prior to surgery will be scheduled for the tumor to be injected with a hydrogel and TCE (T-Cell Engager) combination. Prior to the injection the patient will be pre-medicated with diphenhydramine. After the injection, the patient will be monitored for local or systemic reaction and then be admitted to the ICU for overnight observation. If any issues develop the patient will be treated as warranted by their clinical signs and treatment costs directly related to the study will be paid for by the study. The patient will be discharged the following day, and the owner will monitor their pet for 1 week at home for an adverse reaction to the injection. Photographs will be taken at regular intervals to document any adverse reactions. One week after injection the tumor will be surgically removed and sent for histopathology and evaluation of the injection site.
Owner responsibilities
- Owners must be willing to fulfill standard of care associated with surgical removal of the tumor from their dog, including the costs of appointments and diagnostics associated with treatment.
- Owners must be willing to make repeat visits to the WSU VTH for monitoring and treatment.
- Owners must agree to monitor and photograph injections sites at home.
Contact information
Jennifer Heusser
Clinical Studies Coordinator
cell: 509.592.3668
jpmarcus3@wsu.edu